metronidazole monosuccinate profile

Metronidazole monosuccinate is a prodrug of metronidazole, a widely used antibiotic with activity against anaerobic bacteria and protozoa. It is synthesized by reacting metronidazole with succinic anhydride. Metronidazole monosuccinate is absorbed more readily than metronidazole itself, leading to higher plasma concentrations of the active drug. It is used to treat a variety of infections, including bacterial vaginosis, giardiasis, and amebiasis. The compound is also being studied for its potential use in the treatment of inflammatory bowel disease and other conditions. Metronidazole monosuccinate is generally well-tolerated, but it can cause side effects such as nausea, vomiting, and diarrhea.'
```

metronidazole monosuccinate: RN given for parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	83212
MeSH ID	M0147713

Synonyms (16)

Synonym
4-[2-(2-methyl-5-nitro-1h-imidazol-1-yl)ethoxy]-4-oxobutanoic acid
metronidazole monosuccinate
13182-87-1
AKOS002273919
4-[2-(2-methyl-5-nitroimidazol-1-yl)ethoxy]-4-oxobutanoic acid
butanedioic acid, mono(2-(2-methyl-5-nitro-1h-imidazol-1-yl)ethyl) ester
einecs 236-130-1
(2-(2-methyl-5-nitro-1h-imidazol-1-yl)ethyl) hydrogen succinate
FT-0682988
metronidazole hemisuccinate
DTXSID00157220
metronidazolmonosuccinat
4-(2-(2-methyl-5-nitro-1h-imidazol-1-yl)ethoxy)-4-oxobutanoic acid
APPATXNXXOVPAY-UHFFFAOYSA-N
CS-0337868
4-(2-(2-methyl-5-nitro-1h-imidazol-1-yl)ethoxy)-4-oxobutanoicacid

Research

Studies (5)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (20.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (80.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.34 (24.57)
Research Supply Index	1.79 (2.92)
Research Growth Index	4.14 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.34)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (20.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	4 (80.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
metronidazole Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.	9.2	5	0	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic

metronidazole monosuccinate

Description